30 closest matches · ranked by relevance
Previously Treated Childhood Rhabdomyosarcoma · Recurrent Childhood Rhabdomyosarcoma · Recurrent Childhood Soft Tissue Sarcoma
Primary: Response (Complete Response [CR] and Partial Response [PR]) — 1; 0; 0; 0 participants
Sarcoma
Primary: Response — 10; 0 participants
Sarcoma
Primary: Occurrence of Severe Toxicity — 1; 1 participants
Ewing's Sarcoma
Primary: Objective Response Rate of Olaparib — 0 Participants
Ewing's Sarcoma Family of Tumors
Primary: Objective Response Rate (ORR) — 14.2 percentage of participants
Neuroblastoma · Sarcoma · Rhabdomyosarcoma-Embryonal
Primary: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay — 0; 15 Participants — p=0.043
Sarcoma, Ewing's
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 3; 3; 3 participants
Sarcoma
Primary: Overall Objective Response — 4; 1 participants
Localized Extraskeletal Ewing Sarcoma · Peripheral Primitive Neuroectodermal Tumor of Bone · Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Primary: Event-Free Survival — 77.64; 78.79 Percent Probability
Ewing Sarcoma of Bone · Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Primary: Incidence of Death — 0 participants
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
Ewing Sarcoma of Bone · Extraosseous Ewing Sarcoma · Peripheral Primitive Neuroectodermal Tumor
Primary: The Occurrence of Limiting Toxicity in an Eligible and Evaluable Patient. — 0 number of toxicities
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years
Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET) · Rhabdomyosarcoma · Leiomyosarcoma
Primary: Percentage of Participants With Progression-Free Survival (PFS) at 12 Weeks — 27.3; 12.5; 25.4; 50.0 percentage of participants
Ewing's Sarcoma
Primary: Number of Participants With Adverse Events Determined by Laboratory Assessments and Physical Examinations — 5; 6; 9 Participants
Neoplasms
Primary: Objective Response Rate (ORR) — 50; 30.8; 20; 26.7 Percentage of Participants
Relapsed/Refractory Rhabdomyosarcoma · Non-rhabdomyosarcoma Soft Tissue Sarcoma · Ewing Sarcoma
Primary: Percentage of Participants With Objective Response — 0; 0; 0 percentage of participants
Sarcoma
Primary: Objective Response Rate — 6; 5; 14 participants
Ewing's Sarcoma · Primitive Neuroectodermal Tumor (PNET) · Askin's Tumor of the Chest Wall
Primary: Overall Response Rate (ORR) — 0 Participants
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Neuroblastoma · Sarcoma
Primary: Objective Response Rate
Adult Angiosarcoma · Adult Epithelioid Sarcoma · Adult Leiomyosarcoma
Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants
Sarcoma
Primary: Incidence of Adverse Events Measured by the National Cancer Institute Common Terminology Criteria for Adverse Events Version (v)4.03 — 1; 1; 1; 1 participants
Sarcoma
Primary: Number of Participants With Grade 3 Bilirubin — 3 participants with Grade 3 Bilirubin
Osteosarcoma · Medulloblastoma · Sarcoma, Ewing's
Primary: Percentage of Participants With Overall Tumor Response (Response Rate) — 0; 0; 0; 0 Percentage of Participants
Sarcoma · Metastatic Disease · Bony Sites
Primary: Lesion-specific Local Control at 6 Months Post-SBRT as Assessed by Percentage of Lesions Locally Controlled — 95 percentage of lesions
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Metastatic Osteosarcoma · Recurrent Adult Soft Tissue Sarcoma
Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)
Relapsed Ewing Sarcoma · Refractory Ewing Sarcoma
Primary: Number of Participants With a Metabolic Response as Evaluated by PERCIST v1.0 — 1; 2; 4; 3 Participants
Adult Malignant Fibrous Histiocytoma of Bone · Desmoid Tumor · Endometrial Cancer
Primary: Overall Objective Response — 1; 21; 26 participants
Soft Tissue Sarcoma
Primary: Overall Response Rate (ORR) — 9; 3; 6 participants